AbbVie reports positive Phase 3 AFFIRM trial results for risankizumab subcutaneous induction in Crohn’s disease. Discover what the findings mean for treatment.
Glenmark Pharmaceuticals wins FDA approval for generic fluticasone inhaler with 180-day exclusivity. Read what it means for the U.S. asthma drug market.
Ultrasound AI wins FDA De Novo clearance for Delivery Date AI. Discover how predictive ultrasound analytics could change prenatal care and delivery timing.
Theravance Biopharma halted its ampreloxetine program after a Phase 3 failure. Discover what the CYPRESS results mean for the company and the neurogenic hypotension market.
Innoblative’s SIRA device wins AMA Category III CPT code for intraoperative breast cancer ablation. Discover what this milestone means for surgery and reimbursement.
XellSmart’s iPSC-derived neuron therapy enters MSA-P trials after FDA and NMPA clearances. Discover what this means for regenerative neurology.
RTX-117 enters Phase 1 trials as an AI-designed therapy for Charcot-Marie-Tooth disease and VWM. Discover what this milestone means for rare disease drug discovery.
Life Recovery Systems begins pivotal ThermoSuit stroke trial to test rapid cooling therapy. Discover what this could mean for neuroprotection in ischemic stroke.
Scinai Immunotherapeutics seeks €12M EU funding to advance PC111 for rare autoimmune skin diseases. Explore the clinical, regulatory, and industry implications.
Precision Biologics highlights tumor-specific monoclonal antibodies at Festival of Biologics USA. Discover how neoepitope targeting could reshape cancer therapy.